Статті в журналах: "62-1/-9"

1

Saqeb, Khan Md Nazmus, Deepankar Kumar Basak, and Mohammad Shamsul Arfin. "Idiopathic Colonic Varix: Presenting as Lower GI Bleeding in an Elderly Male." Bangladesh Critical Care Journal 9, no. 1 (April 18, 2021): 62–64. http://dx.doi.org/10.3329/bccj.v9i1.53063.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Stinear, T., A. Matusan, K. Hines, and M. Sandery. "Detection of a Single Viable Cryptosporidium parvum Oocyst in Environmental Water Concentrates by Reverse Transcription-PCR." Applied and Environmental Microbiology 63, no. 2 (February 1997): 815. http://dx.doi.org/10.1128/aem.63.2.815-815d.1997.

Повний текст джерела

Анотація:

Volume 62, no. 9, p. 3386, column 1, last line: "(specific gravity, 2.10) and centrifuging the mixture at 2,000 x g for 10 min" should read "(specific gravity, 1.10) and centrifuging the mixture at 1,050 x g for 10 min." Page 3387, column 1, line 16: "25 cycles at 90(deg)C for 5 min" should read "25 cycles at 90(deg)C for 5 s." [This corrects the article on p. 3385 in vol. 62.].

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Acosta Z., Maritza, Manuel Tantaleán V., and Enrique Serrano-Martínez. "Identificación de Parásitos Gastrointestinales por Coproscopía en Carnívoros Silvestres del Zoológico Parque de las Leyendas, Lima, Perú." Revista de Investigaciones Veterinarias del Perú 26, no. 2 (June 3, 2015): 282. http://dx.doi.org/10.15381/rivep.v26i2.11000.

Повний текст джерела

Анотація:

El presente trabajo tuvo por objetivo identificar los parásitos gastrointestinales de carnívoros silvestres del Zoológico Parque de Las Leyendas en el Perú, mediante la aplicación de cuatro métodos coproparasitológicos convencionales (directo, de Ritchie modificado, Sheather y la coloración de Ziehl Neelsen). Se trabajó con 62 ejemplares pertenecientes a 17 especies de seis familias. El 25.8% (16/62) de las muestras fueron positivas a parásitos. Panthera leo, Panthera tigris y Lycalopex sechurae fueron las especies más parasitadas (9/9, 2/3 y 3/5, respectivamente). Los parásitos identificados fueron el nematodo Toxascaris leonina (12/16), el acantocéfalo Corynosoma sp (3/16), el cestodo Atriotaenia sp (1/6) y el protozoo Giardia sp. (1/16). No se encontró asociación estadística entre las variables de edad y sexo.

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Ewel, Katherine C., Wendell P. Cropper.Jr., and Henry L. Gholz. "Soil CO2 evolution in Florida slash pine plantations. II. Importance of root respiration." Canadian Journal of Forest Research 17, no. 4 (April 1, 1987): 330–33. http://dx.doi.org/10.1139/x87-055.

Повний текст джерела

Анотація:

Respiration of live roots was the single largest contributor to soil CO2 evolution in two mature slash pine (Pinuselliottii) plantations. Root respiration accounted for 51% of soil CO2 evolution at the 9-year-old plantation and 62% at the 29-year-old plantation. Additional estimates, calculated from data recorded from two small trenched plot sites at the 29-year-old plantation and based on possible variations in initial root biomass and subsequent decomposition rates, also averaged 62% of soil CO2 evolution. Specific root respiration averaged 0.40 g•g−1•year−1, varying from 0.34 to 1.70 g•g−1•year−1. Plots with larger proportions of fine roots had faster soil CO2 evolution rates.

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Lindstrom, Wayne. "The Writing of My Constitution." Methodist DeBakey Cardiovascular Journal 9, no. 1 (January 2013): 62. http://dx.doi.org/10.14797/mdcj-9-1-62.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Jacques, G. "Norman Lewis: An appreciation." Nka Journal of Contemporary African Art 1998, no. 9 (September 1, 1998): 62–63. http://dx.doi.org/10.1215/10757163-9-1-62.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Kozhanov, Aleksandr Ivanovich, and Regina Rafailovna Safiullova. "Determination of parameters in telegraph equation." Ufimskii Matematicheskii Zhurnal 9, no. 1 (2017): 62–74. http://dx.doi.org/10.13108/2017-9-1-62.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Li, Bin, Jun Bai, Lingjun Zhu, Sen Zhang, Guihua Wang, Pingping Dai, Jiaojiao Huan, et al. "Application of next generation sequencing (NGS) in gastrointestinal stromal tumor (GIST)." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): e13675-e13675. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e13675.

Повний текст джерела

Анотація:

e13675 Background: The majority of GISTs harbor activating mutations in KIT or PDGFRA. However, the clinical relevance of other genomic alterations, tumor mutation burden(TMB), microsatellite instability(MSI) as well as ctDNA-based clinical utility were poorly examined. Methods: A total of 106 samples obtained from 92 patients (Table) were sequenced by NGS with 1021 cancer-associated gene panel. Results: In 62 treatment naïve patients, the most common primary localization was stomach (29), followed by small intestine (22). KIT mutations were found in 52 (89.0%) cases. The most frequent alterations occurred in exon 11(48/55), followed by exon 9(6/55) and then exon 17(1/55). The primary foci of GIST patients harboring KIT exon 9 mutations was small intestine mainly. There was one patient presented with PDGFRA mutation in exon 18 (1.9%,1/62). All these cases were absent of BRAF, RAS, PIK3CA mutations, while actionable mutations detected from other genes, including CDKN2A(6/62), NF1(4/62) TSC1(2/62), PTEN(2/62) and BRCA2(2/62). Six (6/62, 10.0%) patients were KIT/ PDGFRA wild type and two of them (33.3%) detected pathogenic mutation in NF1 gene, with diagnosed age at 36 and 38 years old respectively. TMB and MSI status were analysed in 30 GIST using NGS method and no TMB-H or MSI-H sample found. Thirty-six patients who resistance to imatinib or sunitinib were screened. Nine (47.4%) and four patients (16.0%) harbored resistant mutations in KIT gene detected from tumor and blood sample cohort, concurrent sensitive and resistance mutations remain the major subtype (Table). The low percent of ctDNA detection were consistent with previous studies that clinical characteristics (tumor size, Ki67, etc.) could influence the results. Conclusions: Panel-based NGS could comprehensively elucidated the landscape of GIST and identified more tumor-specific genetic alterations which can be managed by targeted therapy. But immunotherapy and liquid biopsies remains challenging and needs further investigation from our results. [Table: see text]

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Almeida, Marcel L., Douglas C. F. Viana, Valécia C. M. da Costa, Flaviana A. dos Santos, Michelly C. Pereira, Maira G. R. Pitta, Moacyr J. B. de Melo Rêgo, Ivan R. Pitta, and Marina G. R. Pitta. "Synthesis, Antitumor Activity and Molecular Docking Studies on Seven Novel Thiazacridine Derivatives." Combinatorial Chemistry & High Throughput Screening 23, no. 5 (July 9, 2020): 359–68. http://dx.doi.org/10.2174/1386207323666200319105239.

Повний текст джерела

Анотація:

Aim and Objective: In the last decades, cancer has become a major problem in public health all around the globe. Chimeric chemical structures have been established as an important trend on medicinal chemistry in the last years. Thiazacridines are hybrid molecules composed of a thiazolidine and acridine nucleus, both pharmacophores that act on important biological targets for cancer. By the fact it is a serious disease, seven new 3-acridin-9-ylmethyl-thiazolidine-2,4-dione derivatives were synthesized, characterized, analyzed by computer simulation and tested in tumor cells. In order to find out if the compounds have therapeutic potential. Materials and Methods: Seven new 3-acridin-9-ylmethyl-thiazolidine-2,4-dione derivatives were synthesized through Michael addition and Knoevenagel condensation strategies. Characterization was performed by NMR and Infrared spectroscopy techniques. Regarding biological activity, thiazacridines were tested against solid and hematopoietic tumoral cell lines, namely Jurkat (acute T-cell leukemia); HL-60 (acute promyelocytic leukemia); DU 145 (prostate cancer); MOLT-4 (acute lymphoblastic leukemia); RAJI (Burkitt's lymphoma); K562 (chronic myelogenous leukemia) and normal cells PBMC (healthy volunteers). Molecular docking analysis was also performed in order to assess major targets of these new compounds. Cell cycle and clonogenic assay were also performed. Results: Compound LPSF/AA-62 (9f) exhibited the most potent anticancer activity against HL-60 (IC50 3,7±1,7 μM), MOLT-4 (IC50 5,7±1,1 μM), Jurkat (IC50 18,6 μM), Du-145 (IC50 20±5 μM) and Raji (IC50 52,3±9,2 μM). While the compound LPSF/AA-57 (9b) exhibited anticancer activity against the K562 cell line (IC50 51,8±7,8 μM). Derivative LPSF/AA-62 (9f) did not interfere in the cell cycle phases of the Molt-4 lineage. However, the LPSF/AA-62 (9f) derivative significantly reduced the formation of prostate cancer cell clones. The compound LPSF/AA-62 (9f) has shown strong anchorage stability with enzymes topoisomerases 1 and 2, in particular due the presence of chlorine favored hydrogen bonds with topoisomerase 1. Conclusion: The 3-(acridin-9-ylmethyl)-5-((10-chloroanthracen-9-yl)methylene)thiazolidine-2,4-dione (LPSF/AA-62) presented the most promising results, showing anti-tumor activity in 5 of the 6 cell types tested, especially inhibiting the formation of colonies of prostate tumor cells (DU-145).

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Alunno, A., M. L. Marques, A. Boonen, L. Falzon, S. Ramiro, and P. Putrik. "AB1177 METHODOLOGICAL ASPECTS OF DESIGN, ANALYSES AND REPORTING OF STUDIES WITH WORK PARTICIPATION AS OUTCOME DOMAIN IN PATIENTS WITH INFLAMMATORY ARTHRITIS: RESULTS OF TWO SYSTEMATIC LITERATURE REVIEWS INFORMING EULAR POINTS TO CONSIDER." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1879.1–1880. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4730.

Повний текст джерела

Анотація:

Background:Inflammatory arthritis (IA) has substantial impact on work participation (WP). However, methodological issues hamper interpretation, comparison and meta-analyses of studies with WP as outcome domain. Sources of heterogeneity and methodological choices should be assessed in order to improve the quality of future studies.Objectives:To summarize methodological choices in studies with WP as outcome domain in IA and other chronic diseases.Methods:A EULAR task force on ‘points to consider (PtC) when designing, analysing and reporting studies with WP as outcome domain among patients with IA’ outlined the scope of the systematic literature review (SLR) and identified 6 areas of potential concern (Table 1). Two searches were conducted (Figure 1): Search 1 (S1): original studies in IA (RCTs and longitudinal prospective observational studies); S2: systematic reviews in other chronic diseases. Two reviewers independently identified eligible studies and extracted data for the pre-defined methodological areas.Table 1.Methodological issues across the 6 pre-defined areas (search 1, n=62)AreaMethodological issues*1. Study design- 16/62 (26%) and 8/62 (13%) studies aligned the target population and sample size with the study’s work outcome.- 9/39 (24%) of the interventional studies aimed to assess changes of work status (employment/disability) over a very short follow-up time (≤6 months).2. Work outcome domains- 7/33 (21%) of studiesdefined work status.- 30/30 (100%), 38/38 (100%) and 7/7 (100%)defined absenteeism, presenteeism and unpaid work, respectively.3. Work outcome measurement instruments- 22/62 (35%) studies usednon-validated instruments(e.g. self-reported days of sick leave/impact of disease on productivity, n=16/62, 26%).4. Contextual factors- 54/62 (87%) studies neglected work-related contextual factors.5. Data analysesOf the studies measuring absenteeism and/or presenteeism:- 10/38 (26%) accounted forskewnessof the work outcome.- 30/38 (79%) tookinterdependencebetween outcomes as part of work productivity and activity impairment questionnaire into account.6. Reporting- 62/62 (100%) studies reported the size and characteristics of the (sub)groups in which the analyses were performed.- 1/62 (2%) reported loss to follow-up and work-related reasons for drop-out.- 42/62 (68%) studies presentedaggregatedresults; 11/62 (18%) presented results aspercentages according to meaningful thresholds; 9/62 (14%): both forms.- 21/24 (88%) studies reportingproductivity costs,provided data on natural volumes (days/hours) used to calculate costs.*The number of studies in denominators vary by methodological issue.Results:We included 62 original studies in IA (23 RCTs, 16 interventional and 23 non-interventional observational studies) and 28 SLRs in other chronic diseases. The methodological aspects most often neglected in original studies (Table 1) were: the choice of the study design in relation to the work-related study objective; definitions of the WP outcome domains considered; accounting for skewness of the work outcome; consideration of work-related contextual factors; reporting attrition and its reasons and reporting both aggregated results as well as proportions of individuals based on predefined meaningful thresholds. SLRs on other chronic diseases confirmed high heterogeneity and methodological flaws in all the 6 key methodological areas without identifying new problematic areas.Conclusion:High methodological heterogeneity was observed in studies with WP. Consensus around the key methodological aspects is needed to homogenise and improve the quality of future studies. This review informs the EULAR PtC for the conduction and reporting of studies with WP as an outcome domain in IA.Disclosure of Interests:Alessia Alunno: None declared, Mary Lucy Marques: None declared, Annelies Boonen Grant/research support from: AbbVie, Consultant of: Galapagos, Lilly (all paid to the department), L. Falzon: None declared, Sofia Ramiro Grant/research support from: MSD, Consultant of: Abbvie, Lilly, Novartis, Sanofi Genzyme, Speakers bureau: Lilly, MSD, Novartis, Polina Putrik: None declared

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Law, Steven, and Andrew Davenport. "Glucose absorption from peritoneal dialysate is associated with a gain in fat mass and a reduction in lean body mass in prevalent peritoneal dialysis patients." British Journal of Nutrition 123, no. 11 (January 29, 2020): 1269–76. http://dx.doi.org/10.1017/s0007114520000306.

Повний текст джерела

Анотація:

AbstractThe majority of peritoneal dialysates use glucose to generate an osmotic gradient for the convective removal of water and Na. Although glucose can potentially be absorbed, previous studies have failed to establish whether this leads to increased fat weight gain. We measured body composition using bioimpedance in peritoneal dialysis (PD) patients, electively starting PD, attending for their first assessment of peritoneal membrane function after 2–3 months, and then after 12 months. We studied 143 patients: eighty-nine (62·2 %) males, fifty-three (37·1 %) diabetics, mean age 61·3 (SD 14·9) years, with ninety (62·1 %) patients treated by automated PD cyclers with a daytime icodextrin exchange and thirty-seven (25·9 %) by continuous ambulatory PD. Median fat mass increased by 1·8 (–0·5 to 4·1) kg, whereas fat-free mass fell –1·3 (–2·9 to 1·0) kg, and the increase in fat mass was negatively associated with the fall in soft lean mass (r –0·41, P < 0·001). Increased fat mass was associated with measured peritoneal glucose absorption (r 0·69, P < 0·001), and glucose absorption was associated with the amount of 22·7 g/l glucose dialysate (OR 2·0, 95 % CI 1·5, 2·5, P < 0·001), peritoneal urea clearance (OR 9·5, 95 % CI 2·4, 37·1, P = 0·001) and male sex (OR 4·8, 95 % CI 1·5, 14·9, P = 0·008). We report an observational study in prevalent PD patients following body composition from their first assessment of PD membrane function for approximately 12 months, and despite the majority of patients prescribed icodextrin, we have demonstrated not only an association between intra-peritoneal glucose absorption and fat weight gain but also loss of fat-free mass.

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Bell, Reginald C. W., Katherine Freeman, Rachel Heidrick, and Shahin Ayazi. "Transoral incisionless fundoplication demonstrates durability at up to 9 years." Therapeutic Advances in Gastroenterology 14 (January 2021): 175628482110048. http://dx.doi.org/10.1177/17562848211004827.

Повний текст джерела

Анотація:

Goals: To assess the long-term results of transoral incisionless fundoplication (TIF 2). Background: TIF with the EsophyX2 is an accepted procedure to treat gastroesophageal reflux disease (GERD). Long-term data have been limited. We report clinical outcomes of 151 patients followed up to 9 years. Study: A single institution prospective registry of patients undergoing TIF 2 between 11/2008 and 7/2015. Outcomes were assessed by complications, re-interventions, and a mixed effect model of clinical response over time. Results: A total of 151 patients (87 women), mean age 62 years (30–91), mean body mass index (BMI) 26.6 (20–36.1), 93% on daily proton pump inhibitor (PPI), underwent TIF 2 without hiatal hernia repair; 131 of the 151 patients (86%) were available for follow-up at a median of 4.92 years (0.7–9.7 years). Of 120 patients ⩾5 years post-TIF, 62 (51%) were followed for a median 6.8 years. Median GERD-health-related quality of life (HRQL) scores decreased from 21 (interquartile range (IQR) 9.5–30) off PPI and 14 (4–24) on PPI at baseline to 4 (2–8) at 4.92 years and remained at 5 (2–9) in the 62 patients 5–9 years post-TIF. Sixty-four per cent had successful (>50%) reductions in GERD-HRQL scores at 4.92 years and 68% of patients followed ⩾5 years. Median regurgitation decreased from 15 (8–20) off PPI and 11 (5–20) on PPI at baseline to 0 (0–4) at 4.92 years, remaining at 1 (0–3) in 62 patients 5–9 years post-TIF. Mixed model analyses confirmed significant and stable improvements in GERD-HRQL and regurgitation scores at all annual follow-up time points after TIF. Daily PPI use decreased from 93% to 32% at 4.92, and 22% at ⩾5 years post-TIF. Revision to laparoscopic fundoplication in 33(22%) showed comparable outcomes. Two patients recovered uneventfully after laparoscopic surgery for localized perforation. Conclusions: TIF 2 provides durable relief of GERD symptoms at up to 9 years with 69–80% of patients having a successful outcome by symptom response and PPI use.

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Turley, Kenneth R., Jack H. Wilmore, Bruce Simons-Morton, Jean M. Williston, Jackie Reeds Epping, and Ginny Dahlstrom. "The Reliability and Validity of the 9-Minute Run in Third-Grade Children." Pediatric Exercise Science 6, no. 2 (May 1994): 178–87. http://dx.doi.org/10.1123/pes.6.2.178.

Повний текст джерела

Анотація:

This study was designed to determine the validity and reliability of the 9-min distance run in assessing cardiorespiratory fitness in third-grade children. Fifty-one children (27 girls and 24 boys) participated in at least one maximal cycle ergometer test to determine peak oxygen consumption (V̇O2peak) and in two 9-min runs. Significant (p < .01) test-retest intraclass correlations indicated that both the peak cycle ergometer test and the 9-min run were reliable measures in boys and girls and when the total sample was combined. Interclass correlations of r = .62 and r = .64 were attained between V̇O2peak (ml·kg−1·min−1) and 9-min Run 1 and 9-min Run 2, respectively. When data were separated by gender, 9-min Run 1 and 9-min Run 2 correlated to V̇O2peak (r = .56 and r = .48 for the girls and r = .65 and r = .71 for the boys, respectively). These results suggest that the 9-min distance run is a reasonably valid and highly reliable field test for estimating cardiorespiratory fitness in third-grade children.

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Parcelier, Anne, Isabelle Leduc, Lavinia Merlusca, Gandhi Damaj, Amandine Charbonnier, Berengere Gruson, Saliha Sid-Idris, Jean Pierre Marolleau, and Bruno Royer. "Outcome and treatment of 62 Patients Aged Over 75 Years with Low Grade Non Hodgkin Lymphoma." Blood 120, no. 21 (November 16, 2012): 4854. http://dx.doi.org/10.1182/blood.v120.21.4854.4854.

Повний текст джерела

Анотація:

Abstract Abstract 4854 The incidence of B cell Non Hodgkin Lymphoma (NHL) is steadily increasing with age and about 40% of cases occur in patients aged over 70 years. Some series have reported that low grade NHL lymphomas represent about 35% of all B NHL in elderly patients. However few data are available on the outcome of patients aged over 75 years. Methods We report in a retrospective study the outcome and management of 62 patients aged over 75 years and followed between Jan, 2006, and Jan, 2012 from 2 french centers (Amiens, Abbeville). The primary endpoint was overall survival (OS); secondary endpoints were response rates, progression free survival (PFS), and toxicity. Results 62 patients were registered with median age of 80,4 years (75–92): 31 patients with follicular lymphomas (FL) and 31 other low grade LNH: 15 Marginal Zone Lymphomas (MZL) of witch 11/31 splenic MZL, 1 gastric MALT, 5 lymphoplasmocytic and 10 lymphocytic lymphomas. At diagnostic, evaluation included: computed tomography scan for 46/62 patients (76%), bone marrow biopsy: 17/62 (27%), abdominal echography for 13/62 (24%) patients, echocardiography 24/62 (39%) and positron emission tomography for 11/62 (17%) patients. Charlson score (0–27) was evaluable for all of them with a median score of 2(0–4). At analysis, the median follow up was 23 months (range 0–79). Median FLIPI was 3 (0–5) for FL and median IPI 3(0–5) for other NHL. 21/31 (68%) FL patients and 27/31 (87%) other NHL had stage III or IV in the Ann Arbor classification. 47/62 (76%) patients received chemotherapy: 27/31 (89%) FL patients and 20/31 (65%) with other NHL. 12/62 (19%) patients were undergoing watchfull waiting (11 patients with other NHL, 1 FL); 1 patient refused chemotherapy; 1 FL patient died before any treatment. 29/47 (61%) treated patients received Rituximab (R). In the FL group, 12/31 (39%) received RCVP (C=Cyclophosphamide, V=Etoposide, P=Prednisone), 12/31 (39%) RCHOP-like regimen, 2/31 (6%) chlorambucil, 1/31 (3%) corticotherapy alone, 1/31 (3%) radiotherapy alone and 2/31 (6%) chemotherapy plus radiotherapy. For other low grade NHL, 2/31 (6%) received RCVP, 3/31 (9%) RCHOP-like regimen, 10/31 (32%) Chlorambucil, 1/31(1%) Fludarabine, 4/31(13%) orally cyclophosphamide and corticosteroid. 17 on 47 treated patients (36%) were in complete remission: 10/27 (37%) FL and 7/20 (35%) other NHL. The 2-years OS was 67%: 61% in the FL group and 74% other NHL (difference not significative); the 2-years PFS was 68%: 60% for FL and 77% for other low grade NHL. In univariate analysis, OS was affected by IPI (p=0,02) and FLIPI (p=0,008) (figure), but not by serum albumin concentration ≤ 35g/L, lymphopenia ≤1G/L, or Charlson score. 25 deaths were reported (14 FL and 11 other NHL): 9 lymphoma progressions, 6 sepsis, 3 attributed to cardiac failure and 1 to pulmonary embolism. The most frequent side-effects were hematological: febrile neutropenia (15 patients) and cardiac: acute failure (4 patients). Conclusion Our results in older patients with low grade lymphoma compare favorably with results in younger population. IPI and FLIPI only affect OS whereas geriatric evaluation with Charlson score is not relevant, possibly due to the small number of patients and short follow-up. These results prompt us to realize prospective studies in this population, reducing toxicity and improving efficacy with novel approach. Disclosures: No relevant conflicts of interest to declare.

Стилі APA, Harvard, Vancouver, ISO та ін.

15

GHOSH, S., V. VARGHESE, M. SINHA, N. KOBAYASHI, and T. N. NAIK. "Evidence for interstate transmission and increase in prevalence of bovine group B rotavirus strains with a novel VP7 genotype among diarrhoeic calves in Eastern and Northern states of India." Epidemiology and Infection 135, no. 8 (February 12, 2007): 1324–30. http://dx.doi.org/10.1017/s0950268806007813.

Повний текст джерела

Анотація:

SUMMARYDuring a surveillance study (2003–2005) in a cattle market in Kolkata city, state of West Bengal, Eastern India, 34 (13·0%) of 260 calves with diarrhoea were positive for group B rotaviruses (GBR) by RNA electrophoresis in polyacrylamide gels. Analysis of the partial VP7 gene sequence of 28 of the 34 GBR strains revealed maximum identities (97·7–99·5% at nucleotide level and 97·8–100% at amino-acid level) with the novel bovine GBR ‘Kolkata strains’ reported in an earlier surveillance study (1·5%,n=192, 2001–2002) from the same cattle market, and shared low identities of 73·7–78·9% and 80·8–89·6%; 62·6–66·2% and 59·8–65·4%; 58·9–62·2% and 48·6–54·9% at nucleotide and amino-acid level with other bovine, human, and murine GBR. The GBR-infected calves were traced to districts in neighbouring states of West Bengal. Therefore, the present study reports a rapid increase in prevalence (13·0% in 2003–2005 against 1·5% in 2001–2002) of novel GBR strains among calves with diarrhoea, and provides evidence for interstate transmission of GBR.

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Sunkara, Rajitha, Charu Taneja, Dorcas Chi, Gail Wolfe, Christine Segal, Allison Keel, Phoebe Olhava, and Leslie A. Martin. "Role of sentinel lymph node biopsy (SLNB) and preoperative MRI in the management of patients with pure high-grade ductal carcinoma in situ (DCIS)." Journal of Clinical Oncology 31, no. 26_suppl (September 10, 2013): 87. http://dx.doi.org/10.1200/jco.2013.31.26_suppl.87.

Повний текст джерела

Анотація:

87 Background: The overall incidence of SLN metastases in pure DCIS is < 1% and the results of SLNB do not usually impact treatment or survival but adds significant surgical morbidity. In addition, there is no evidence regarding the role of preoperative MRI in the management of DCIS. The purpose of our study was to identify the efficacy of SLNB and the benefit of preoperative MRI in high-grade DCIS. Methods: We performed retrospective review of 364 patients with DCIS, identified through our cancer registry database, that were seen from 2003 to 2012 at our institution. Of these, 62 patients were diagnosed with high-grade DCIS (Grade 3 or 2 with comedonecrosis) by core needle biopsy, and underwent SLNB. The remaining 302 patients had either low-grade DCIS or did not have a SLNB. Results: Median age was 56 years (range 33-80). Sixty two patients had high-grade DCIS on definitive excision and 2/62 patients were noted to have small invasive focus of disease. 15/62 (24.19%) patients underwent mastectomy and 47/62(78.1%) underwent lumpectomy. No patient had a positive SLN (0/62). 15/62 (24.2%) patients had breast MRI preoperatively and among them, in 5 (33.3%) patients, MRI findings changed the surgical decision to mastectomy. Among these 5 mastectomy patients, four of them (80%) had pathologically confirmed findings consistent with preoperative MRI suspicions. In lumpectomy patients, close margin of less than 1mm was seen in 4/9 (44.4%) patients with staging MRI and in 24/38 (63.15%) patients without MRI (p = 0.45. Fisher’s exact test). However the positive margin leading to re-excision was seen in 2/9 (22.2%) patients who underwent lumpectomy with staging MRI, and 9/38 (23.6%) patients who underwent lumpectomy without staging MRI. Conclusions: In our study, no patient with high grade DCIS had a positive sentinel node suggesting that routine sentinel node biopsy is not necessary in DCIS patients. The use of MRI changed the surgical planning in 33.3% of patients, but did not improve the surgeon's ability to achieve clear margins.

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Stacchiotti, Silvia, Patrick Schoffski, Robin Jones, Mark Agulnik, Victor Manuel Villalobos, Thierry Marie Jahan, Tom Wei-Wu Chen, et al. "Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950)." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 11003. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.11003.

Повний текст джерела

Анотація:

11003 Background: ES is a rare soft tissue sarcoma that metastasizes in approximately 30% to 50% of cases. More than 90% of ES tumors lack expression of INI1, an important component of epigenetic regulation. Loss of INI1 function allows another epigenetic modifier, EZH2, to become an oncogenic driver in tumor cells. Tazemetostat, a first-in-class, selective, oral inhibitor of EZH2, has demonstrated tumor regression and favorable safety in phase 1/2 trials. Methods: Data from a phase 2 open-label, multicenter trial of pts with locally advanced or metastatic ES are reported. Efficacy was assessed with primary and secondary endpoints including objective response rate (ORR) by RECIST 1.1, disease control rate (DCR; objective confirmed response of any duration or stable disease [SD] lasting ≥32 weeks), duration of response (DOR), progression-free survival (PFS), overall survival (OS); safety and tolerability were also evaluated. Results: As of September 17, 2018, 62 INI1-negative ES pts were enrolled and treated with tazemetostat 800 mg BID. The median number of prior lines of therapy was 1 (range: 0-9). There were 9/62 (15%) confirmed partial responses (PRs) with an ORR of 15% and DCR of 26%. The DOR ranged from 7.1+ weeks to 103.0+ weeks (median: not reached) with a median OS of 82.4 weeks (95% CI: 47.4, not estimable) for all 62 pts. Tazemetostat was generally well tolerated. Treatment-emergent adverse events (TEAEs) were generally mild to moderate with the most commonly reported adverse events (AEs; ≥10% incidence) regardless of attribution being fatigue (24/62; 39%), nausea (22/62; 35%), and cancer pain (20/62; 32%). Any treatment-related TEAEs of grade ≥3 were reported in 10/62 (16%) pts. TEAEs grade ≥3 reported in ≥2 pts included anemia (6%) and decreased weight (3%). There were no drug-related deaths and a low discontinuation rate (1.7%). Conclusions: In the largest prospective clinical trial of ES to date, tazemetostat achieved disease control in 26% of pts with advanced ES who entered this study. Durable clinical response of the drug was documented. Tazemetostat demonstrated favorable safety with few pts with treatment-related AEs grade ≥3. Clinical trial information: NCT02601950.

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Ningshen, S., M. Sakairi, K. Sukuki, and S. Ukai. "Corrosion Resistance of 9 - 15% Cr ODS Steels and its Comparison with Austenitic Stainless Steel." Advanced Materials Research 794 (September 2013): 575–82. http://dx.doi.org/10.4028/www.scientific.net/amr.794.575.

Повний текст джерела

Анотація:

An oxide dispersion strengthened steels are one of the most promising high temperatures, and high performance advanced structural material being developed for future fast reactors and high-temperature Generation IV reactors. In the present work, the corrosion resistance and its correlation with the passive film compositions of 11% Cr F/M and 9-15% Cr (with Zr or Hf) ODS steels is examined and compared with AISI type 304L stainless steel in boiling 60 - 62% (~13 M) HNO3. The corrosion rate measured in 62% HNO3 for 240 h of 11% Cr F/M, 9% Cr and 15% Cr (Zr) ODS steels show high corrosion rate. On the other hand, low corrosion rate was observed in 304L stainless steel (0. 21 to 23 mm y-1). However, severe intergranular corrosion attack was revealed in type 304L SS after 240 h exposure, but none in ODS steels. Such an intergranular corrosion attack seen in type 304L stainless steel is undesirable. On the contrary, low corrosion rate (0.04 0.15 mm y-1) of 15% Cr (Hf) ODS steel in 3 M, 6 M and 9 M HNO3, comparable to that of type 304L stainless steel was observed. The improved corrosion resistance of 15% Cr (Hf) ODS steel was attributed to enrich (20 at. %) and protective Al2O3 layer formation in addition to Cr2O3 in the passive film.

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Lynch, G. A., M. E. Hunt, and S. N. McCutcheon. "A note on the effect of monensin sodium administered by intraruminal controlled-release devices on productivity of dairy cows at pasture." Animal Science 51, no. 2 (October 1990): 418–21. http://dx.doi.org/10.1017/s0003356100005572.

Повний текст джерела

Анотація:

The effects of monensin sodium, administered by intraruminal controlled-release devices at a rate of 320 mglday, on milk and milk solids production and bloat score were examined in a trial with 90 lactating dairy cows given only mixed ryegrasslwhite clover pasture. Monensintreated cows had significantly greater yields of milk and milk protein than control cows (1397·2 (s.e. 22·9) v. 1296·9 (s.e. 16·3) kg milk, 49·6 (s.e. 0·9) v. 46·5 (s.e. 0·6) kg protein) over the 14-week period of treatment (P < 0·01). Yield of fat was similar in monensin-treated and control cows (62·9 (s.e. 1·5) v. 63·4 (s.e. 1·1) kg). Live weight, condition score and bloat score were not influenced by treatment but pasture conditions were not conducive to severe bloat challenge.

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Armstrong, A., J. Brewer, C. Newman, V. Alakhov, G. Pietrzynski, S. Campbell, P. Corrie, M. Ranson, and J. W. Valle. "SP1049C as first-line therapy in advanced (inoperable or metastatic) adenocarcinoma of the oesophagus: A phase II window study." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 4080. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.4080.

Повний текст джерела

Анотація:

4080 Background: SP1049C (a block co-polymer incorporating doxorubicin) has demonstrated broad in vitro activity and superior anti-tumour activity in 9/9 in vivo animal tumour models compared to doxorubicin. Methods: Chemotherapy- or radiotherapy-naïve patients with measurable, inoperable, recurrent or metastatic adenocarcinoma of the oesophagus; KP ≥60; normal cardiac LVEF; adequate swallowing and adequate renal, hepatic and bone marrow function were eligible. SP1049C 75mg/m2 IV 30-minute infusion was given q3w, for up to 6 cycles. Radiological response was assessed after cycles 2, 4 and 6. Upon disease progression (PD) patients were offered standard chemotherapy. QoL (by QLQ-C30 and QLQ-OES24 questionnaires), toxicity, disease-related symptoms and cardiac function were also prospectively assessed. Results: From February 2002 to December 2004, 21 patients (all male), median age 62 years (range 38–78) with stage 3 (n = 1) of stage IV (n = 20) disease were enrolled. Response rate (WHO criteria) in 19 patients eligible for efficacy analysis (radiologically re-assessed after ≥2 cycles of treatment) included: PR 9/19 (47%), SD (8/19) 42% and PD (2/19) 11% by investigator assessment (confirmed PR 41%, unconfirmed PR 12% and SD 29% by independent review, RECIST criteria). One responding patient underwent salvage resection of a pT2N0 (Stage 2A) tumour. All patients are evaluable for toxicity. Toxicity (Gd 1–2/3–4, by patient) included: neutropaenia 24%/62%, leucopaenia 19%/29%, anaemia 38%/5% and thrombocytopaenia 9.5%/0% (resulting in 9 (43%) patients being dose-reduced to 55 mg/m2 at cycle 2), nausea 81%/19%, vomiting 62%/24%, anorexia 52.4%/14%, lethargy 81%/14%, febrile neutropaenia -/29%, mucositis 48%/5%, and Gd 1–2 alopecia in 67%. Grade I cardiotoxicity (fall in LVEF by 10–19% from baseline, CTC v2.0) was seen in 4 (19%) patients. The median overall survival (all patients) is 10 months; four patients received 2nd-line chemotherapy. Conclusions: SP1049C appears to have activity in monotherapy in this patient group and combination studies with other active agents are warranted. [Table: see text]

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Hahn, Theresa, Philip L. McCarthy, Anna Hassebroek, John P. Klein, J. Douglas Rizzo, Susan Parsons, Steven Joffe, and Navneet S. Majhail. "Significant Improvement In Day 100 and 1-Year Overall Survival In Patients Who Underwent Myeloablative Allogeneic Hematopoietic Cell Transplant In the US or Canada Between 1994 and 2005." Blood 116, no. 21 (November 19, 2010): 3509. http://dx.doi.org/10.1182/blood.v116.21.3509.3509.

Повний текст джерела

Анотація:

Abstract Abstract 3509 Allogeneic hematopoietic cell transplantation (alloHCT) has become standard therapy for hematologic disorders and malignancies. We assessed whether overall survival (OS) at 100 days, which represents early transplant-related mortality (TRM), and at one year, which represents disease-related mortality and later TRM, had changed over time. The study population was derived from patients undergoing 38,060 first alloHCTs between 1994–2005 in US and Canadian centers and reported to the CIBMTR. Donor lymphocyte infusions were excluded. Statistical significance was measured using Ptrend over 6 time cohorts to test whether the OS estimates were stable (slope = 0), increasing (slope>0) or decreasing (slope<0) over time. The Day 100 and 1 year OS estimates are shown in the Table. Disease and disease status subgroups were defined a priori, and the OS estimates are not adjusted for any covariates such as age, Karnofsky status, etc. Marked improvements in 100-day survival were seen for all disease and disease status groups examined. Day 100 mortality rates in HLA-matched sibling alloHCT recipients during the most recent period (2004-5) were as low as 2% for CML treated in CP1, 6–8% for AML in CR1 and ALL in CR2, and a modest 12% for MDS. Even in alloHCT recipients with unrelated donors treated in 2004-5, the Day 100 mortality rates ranged from 9–22%, a significant decrease from historical mortality rates of 29–37%. Significant improvements in 1-year OS were noted for all groups undergoing unrelated-donor alloHCT; however, among those undergoing HLA-matched sibling alloHCT, significant improvements in 1-year OS were only seen in patients with CML in CP1 or MDS. OS has improved for many patients undergoing myeloablative alloHCT, which likely reflects improvement in supportive care and better patient/donor selection. Day 100 OS has significantly improved in all patients who received a myeloablative HLA-matched related or unrelated donor alloHCT. Significant improvement in 1-year OS was also experienced by most patients. Table: Overall survival (95% CI) estimates over time HLA-Matched Sibling Myeloablative Allogeneic HCT 1994-5 1996-7 1998-9 2000-1 2002-3 2004-5 Ptrend AML in CR1 N 370 370 383 376 384 440 <0.001 @100 days 85 (81–88) 87 (84–90) 90 (86–93) 88 (84–91) 92 (89–94) 94 (91–96) 0.1662 @1 year 69 (65–74) 70 (66–75) 72 (67–76) 67 (62–72) 74 (69–78) 75 (71–80) ALL in CR2+ N 179 186 149 159 156 163 0.0018 @100 days 77 (70–83) 82 (76–87) 88 (82–93) 85 (79–90) 85 (79–90) 92 (87–96) 0.2937 @1 year 62 (55–69) 63 (56–70) 69 (61–77) 59 (51–67) 64 (56–71) 70 (62–77) CML in CP1 N 483 540 492 317 155 125 <0.001 @100 days 84 (81–87) 88 (85–90) 89 (87–92) 91 (87–94) 99 (96–100) 98 (94–100) <0.001 @1 year 71 (66–75) 72 (68–76) 80 (76–83) 82 (77–86) 89 (83–93) 92 (86–96) MDS N 225 290 273 235 239 227 <0.001 @100 days 71 (65–77) 75 (70–80) 76 (71–81) 82 (77–87) 85 (80–89) 88 (84–92) 0.0488 @1 year 54 (48–61) 51 (45–57) 57 (51–63) 58 (51–65) 61 (55–68) 64 (58–71) Unrelated Donor Myeloablative Allogeneic HCT 1994-5 1996-7 1998-9 2000-1 2002-3 2004-5 Ptrend AML in CR1 N 52 75 88 135 182 336 <0.001 @100 days 63 (50–76) 64 (53–74) 69 (59–78) 75 (68–82) 82 (76–87) 86 (82–90) 0.0427 @1 year 48 (35–62) 35 (25–47) 48 (37–59) 51 (42–60) 54 (46–61) 56 (50–62) ALL in CR2+ N 129 151 132 116 164 197 <0.001 @100 days 66 (58–74) 70 (62–77) 71 (62–78) 75 (67–82) 78 (71–84) 91 (87–95) <0.001 @1 year 43 (34–51) 45 (37–53) 49 (40–58) 40 (31–50) 54 (46–62) 67 (60–74) CML in CP1 N 211 250 292 152 87 118 0.0006 @100 days 71 (65–77) 70 (64–75) 74 (69–79) 75 (68–81) 80 (71–88) 87 (81–93) 0.0057 @1 year 51 (44–57) 54 (48–61) 59 (53–64) 60 (52–68) 65 (54–75) 71 (62–80) MDS N 104 138 135 140 161 234 <0.001 @100 days 64 (54–73) 62 (54–70) 59 (51–67) 67 (59–75) 74 (67–81) 78 (72–83) <0.001 @1 year 41 (31–50) 44 (35–52) 35 (27–43) 45 (37–54) 52 (44–60) 57 (50–63) Disclosures: No relevant conflicts of interest to declare.

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Garba, Jean Koffi, Ruland Tchuinkeu Nguengang, Gwladys Tatiana Youmbi, Joel Njopnu Menatche, Cyrille Armel Njanpa Ngansop, Jean Jules Kezetas Bankeu, Jean Rodolphe Chouna, Fabrice Fekam Boyom, Norbert Sewald, and Bruno Ndjakou Lenta. "Antileishmanial, antibacterial and cytotoxicity activity of the extracts, fractions, and compounds from the fruits and stem bark extracts of Pentadesma butyracea Sabine." Zeitschrift für Naturforschung B 77, no. 1 (October 21, 2021): 9–15. http://dx.doi.org/10.1515/znb-2021-0077.

Повний текст джерела

Анотація:

Abstract The search for antileishmanial plants used in traditional medicine led to the choice of CH2Cl2–MeOH (1:1) crude extract of the fruits and stem bark of Pentadesma butyracea Sabine (Clusiaceae) which displayed good activity in vitro against Leishmania donovani 1S (MHOM/SD/62/1S) promastigotes during preliminary screening with IC50 values 5.96 and 26.43 μg mL−1, respectively. The fractionation of both extracts using flash chromatography yielded active fractions with IC50 values ranging from 2.71 to 18.88 μg mL−1. Fourteen compounds (1–14) were isolated from the obtained fractions using successive column chromatographies and their structures were elucidated based on the analysis of their NMR and MS data. Daphnifolin (1), epicathechin (3), α-mangostin (9) and 9-hydroxycalabaxanthone (14) exhibited potent antileismanial activity against L. donovani 1S (MHOM/SD/62/1S) promastigotes with IC50 values of 2.01, 9.09, 3.37, and 6.87 μg mL−1, respectively and good selectivity towards Raw 264.7 macrophage cells (SI > 2.4). Extracts, fractions and some isolates were also assessed in vitro for their antibacterial activity against six bacterial strains [Salmonella typhi (CPC), Enterobacter cloacae (CPC), Pseudomonas aeruginosa HM801, Staphylococcus aureus ATCC 43300, Streptococcus pneumoniae ATCC 491619, Escherichia coli ATCC 25322] using serial microdilution method. Among the tested samples, the stem bark extract of P. butyracea as well as compounds 2 and 8 showed good to moderate activity against the aforementioned bacterial strains with MIC ≤ 250 μg mL−1.

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Carroll, Lauren N., Rebecca E. Calhoun, Cleo C. Subido, Ian S. Painter, and Hendrika W. Meischke. "Serving Limited English Proficient Callers: A Survey of 9-1-1 Police Telecommunicators." Prehospital and Disaster Medicine 28, no. 3 (March 28, 2013): 286–91. http://dx.doi.org/10.1017/s1049023x13000265.

Повний текст джерела

Анотація:

AbstractIntroductionThe emergency telephone number 9-1-1 serves as a lifeline to the public during emergencies, and first responders rely on information gathered by 9-1-1 telecommunicators who speak with callers. Timely, accurate information from the telecommunicators is essential for providing appropriate care on scene. Language barriers can hamper these efforts and result in less efficient information exchange. Although 9-1-1 telecommunicators may access over-the-phone interpreter (OPI) services to facilitate communication, managing three-way communication during an emergency is challenging.ProblemThere is little published on the relationship between limited English proficient (LEP) callers and 9-1-1 police telecommunicators, and the role of OPI services during these calls. Further, little is known about effective strategies to manage such calls.MethodsIn King County, Washington, 9-1-1 police telecommunicators were surveyed about their experiences handling LEP calls and managing three-way communication with OPI services. The survey contained 13 multiple-choice and three open-response questions addressing communication strategies, challenges with LEP callers, and three-way communication with OPI services. Goodman-Kruskal Gamma and chi-square tests were conducted with OPI use as the dependent variable. Additional analyses were conducted using stress levels as the dependent variable.ResultsOf 123 respondents, 69 (56.5%) 9-1-1 telecommunicators reported utilizing OPI services at least 75% of the time when receiving a call from an LEP caller. Further, 35 (28.7%) of these telecommunicators reported calls with LEP individuals as more stressful than calls with fluent English speakers. Dispatcher stress level during LEP calls compared with stress during calls with fluent English speakers was positively associated with use of OPI services (P < .01). Further, stress level was also positively associated with telecommunicator difficulties in assessing the situation with respect to officer safety (P < .01). Sixty-three (58.3%) of the telecommunicators described difficulties assessing the situation to determine the appropriate response as the biggest challenge with LEP callers. Additionally, 62 (53%) identified knowing their location in English as information LEP callers need to know prior to calling 9-1-1.ConclusionThese results highlight intervention opportunities for both 9-1-1 telecommunicators and LEP communities. Together, interventions such as working with LEP communities to educate them on best communication practices during 9-1-1 calls, and with 9-1-1 telecommunicators to help them manage three-way communication and reduce stress associated with concern for officer safety may improve emergency communication during 9-1-1 calls.CarrollLN, CalhounRE, SubidoCC, PainterIS, MeischkeHW. Serving limited English proficient callers: a survey of 9-1-1 police telecommunicators. Prehosp Disaster Med. 2013;28(3):1-6.

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Savard, Marie-France, and Nathalie A. Johnson. "Risks and Benefits of Rituximab Maintenance in Elderly Patients with Advanced Follicular Lymphoma." Blood 128, no. 22 (December 2, 2016): 5329. http://dx.doi.org/10.1182/blood.v128.22.5329.5329.

Повний текст джерела

Анотація:

Abstract Introduction: Based on the PRIMA trial (Lancet 2010; 377: 42-51), rituximab maintenance following induction rituximab-based chemotherapy is the standard of care in patients with advanced follicular lymphoma (FL) because it extended the 3-year progression free survival (PFS) from 58% to 75%, with a low rate of infection (<5%). However, this study was conducted in young patients (median age 57 years old) and the benefits and risks of the maintenance are unknown in elderly patients. Methods: We reviewed the clinical characteristics, outcome and complications of 62 advanced FL patients selected based on having successfully completed induction chemotherapy and initiated maintenance rituximab at the Jewish General Hospital between 2007 and 2014. The age cut off of ≥75 years old at the time of treatment was defined as "elderly". We compared characteristics of the two groups using the χ2 test and calculated PFS using the Kaplan-Meier method and log-rank test. Results: In total, 9/62 (15%) patients were "elderly" and 53/62 (85%) were "young", with median ages of 79 (75-87) and 55 (30-74) years old, respectively. Elderly patients had more adverse prognostic features compared to younger patients: B symptoms (4/9 vs 7/53, p=0.023), elevated lactate dehydrogenase (5/9 vs 9/51, p=0.013), lower hemoglobin (5/9 vs 3/52, p<0.001) and poor performance status (3/9 vs 1/53, p<0.001). The mean PFS was lower in elderly patients (25 months vs 65 months, p=0.05). The 3-year PFS in the young group was 80%. Toxicities were higher in the elderly group: grade 3-4 neutropenia (3/9 vs 5/53, p=0.05) and infections (5/9 vs 13/52, p=0.063). Conclusion: Elderly patients had more adverse prognostic factors and a significantly inferior PFS with rituximab maintenance compared to younger patients. The rates of infections were higher than those reported in the PRIMA trial. Maintenance rituximab may not benefit elderly patients with advanced FL. Disclosures No relevant conflicts of interest to declare.

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Палиенко, Сергей Владимирович. "ДОЛГИЙ ПУТЬ ОДНОЙ ОБОБЩАЮЩЕЙ РАБОТЫ (О ПОДГОТОВКЕ «ОЧЕРКОВ ДРЕВНЕЙ ИСТОРИИ УКРАИНЫ» В ИНСТИТУТЕ АРХЕОЛОГИИ АН УССР)". Археология Евразийских степей, № 5 (29 жовтня 2021): 68–74. http://dx.doi.org/10.24852/2587-6112.2021.5.68.74.

Повний текст джерела

Анотація:

Статья посвящена истории написания «Очерков древней истории Украинской ССР» – первой обобщающей работы, подготовленной сотрудниками киевского Института археологии АН УССР. Начатая в 1948 году и запланированная на два года, она затянулась на восемь лет, сама же книга была издана только в 1957. Тексты несколько раз переделывались, иногда писались заново уже другими авторами. Поэтому можно выделить несколько этапов создания книги: 1948–1950 – первоначальная подготовка текстов; 1951–1952 – первое исправление, связанное с выходом статьи И.В. Сталина; 1953–1955 – полная переделка работы, обусловленная сменой концепции в сторону большей историчности. Это также повлекло изменения и в структуре издания. Помимо влияния политики ещё одной причиной задержки стали просчёты руководства ИА АН УССР в организации работы. Библиографические ссылки Абашина Н.С., Колесникова В.А. Нариси історії Інституту археології // Інститут археології Національної академії наук України. 1918–2014. / Отв. ред. П.П. Толочко. Київ: АДЕФ–Україна, 2015. C. 11–98. Бузько О.В. Початок роботи М. І. Вязьмітіної над працею «Искусство Скифии». Листи з Ленінграда // Музейні читання. Матеріали наукової конференції «Ювелірне мистецтво – погляд крізь віки» (9–11 листопада 2015 р., м. Київ). Київ: Музей історичних коштовностей, 2018. С. 7–14. Бузько О.В., Саєнко В.М. До історії написання М. І. Вязьмітіною праці «Искусство Скифии» // Археологія і давня історія України. Вип. 2 (19). Київ: ІА НАН України. 2016. С. 280–283. Бузько О.В., Саєнко В.М. Марія Вязьмітіна – дослідниця мистецтва Скіфії // Переяславіка. Наукові записки Національного історико-етнографічного заповідника «Переяслав». Вип. 13 (15). / Гол. Ред. О.М. Лукашевич. Переяслав-Хмельницький, 2018. С. 19–22. Клейн Л.С. Феномен советской археологии. СПб.: Фарн, 1993. 128 c Нариси стародавньої історії Української РСР. / Отв. ред. В.Л. Зуц. Київ: АН УРСР, 1957. 632 с. Отчёт Института археологии АН УССР за 1948 г. / НА ИА НАНУ. Ф. 62, оп. 1-доп., д. 1948/2. Отчёт ИА АН УССР за 1949 г. / НА ИА НАНУ. Ф. 62. Оп 1-доп., д. 1949/2. Отчёт ИА АН УССР за 1950 г. / НА ИА НАНУ. Ф. 62. Оп 1-доп., д. 1950/3. Отчёт ИА АН УССР за 1951 г. / НА ИА НАНУ. Ф. 62. Оп 1-доп., д. 1951/1. Отчёт о научно-исследовательской деятельности ИА АН УССР за 1952 г. / НА ИА НАНУ. Ф. 62. Оп 1-доп., д. 1952/2. Отчёт о научно-исследовательской деятельности ИА АН УССР за 1953 г. / НА ИА НАНУ. Ф. 62. Оп. 1-доп., д. 1953/4. Отчёт о научно-исследовательской деятельности ИА АН УССР за 1954 г. / НА ИА НАНУ. Ф. 62. Оп 1-доп., д. 1954/3. Отчёт о научно-исследовательской деятельности ИА АН УССР за 1955 г. / НА ИА НАНУ. Ф. 62. Оп 1-доп., д. 1955/2. Свешникова О.С. Советские археологи в поисках первобытной истории. Историческая интерпретация археологических источников в советской археологии 1930-1950-х гг. Омск: Наука, 2009. 204 с.

Стилі APA, Harvard, Vancouver, ISO та ін.

26

O'Doherty, J. V., and T. F. Crosby. "Blood metabolite concentrations in late pregnant ewes as indicators of nutritional status." Animal Science 66, no. 3 (June 1998): 675–83. http://dx.doi.org/10.1017/s1357729800009243.

Повний текст джерела

Анотація:

AbstractIn a feeding experiment β-hydroxybutyrate (BHB), glucose, albumin, total protein, globulin and urea concentrations in the plasma of twin-bearing ewes were analysed. Mature Suffolk cross ewes were given either formic acid (FA)-treated grass silage or grasslmolassed sugar-beet pulp (MSBP) silage in late pregnancy. The experiment commenced on day 91 of pregnancy and the dietary treatments were FA-treated silage (Tl), FA-treated silage + soya-bean meal (SBM) (T2), MSBP silage (T3), MSBP silage + SBM (T4), FA-treated silage + MSBP (T5), FA-treated silage + MSBP + SBM (T6) or FA-treated silage + 150 g crude protein (CP) per kg concentrate (T7). SBM was given only in the last 22 days of pregnancy aiming for a total CP intake of 220 g per ewe per day. Blood samples were collected by jugular venipuncture from each ewe 3 h following consumption of the morning dietary allowance on days 121, 128, 135 and 142 of pregnancy. Daily metabolizable energy (ME) intakes of 6·8, 11·4, 9·6, 12·8, 10·5, 13·7 and 14·7 (s.e. 0·58) MJ per ewe were recorded for Tl to T7 respectively over the last 3 weeks of pregnancy. Respective CP intakes of 72, 213, 110, 225, 109, 215 and 175 (s.e. 5·64) g per ewe were recorded for Tl to T7 respectively over the last 3 weeks of pregnancy. BHB concentrations (mmol/l) on day 121 of pregnancy of 1·18, 1·25, 0·52, 0·52, 0·56, 0·39 and 0·45 (s.e. 0·17), on day 128 of pregnancy of 1·17, 0·94, 0·52, 0·51, 0·72, 0·62 and 0·39 (s.e. 0·20), on day 135 of pregnancy of 1·53, 0·68, 0·68, 0·66, 0·71, 0·62 and 0·46 (s.e. 0·20) and on day 142 of pregnancy of 1·43, 0·60, 0·62, 0·56, 0·62, 0·56 and 0·63 (s.e. 0·20) were recorded for Tl to T7 respectively. There was a quadratic relationship between plasma BHB concentration and ME intake on days 121 (R2 = 0·538, P < 0·001), 128 (R2 = 0·324, P < 0·001), 135 (R2 = 0·429, P < 0·001)) and 142 (R2 = 0·344, P < 0·002) of pregnancy. There was a positive relationship between plasma glucose concentration and ME intake on day 222 (R2 = 0·208, P < 0·002), 228 (R2 = 0·203, P < 0·05), and 135 (R2 = 0·160, P < 0·02) of pregnancy. Albumin concentrations (gll) on day 128 of pregnancy of 21·8, 21·7, 23·6, 22·9, 22·5, 22·9 and 24·3 (s.e. 0-75), on day 135 of 20·9, 23·6, 24·2, 24·1, 22·4, 24·1 and 23·8 (s.e. 0·75), and on day 142 of 16·9, 22·6, 20·7, 22·2, 20·4, 22·7 and 21·1 (s.e. 1·05) were recorded for Tl to T7 respectively. Plasma albumin concentrations were significantly affected by SBM supplementation (P < 0·05). Despite the lower than generally recommended energy concentrations in T2 to T7, the concentrations of plasma BHB were within the normal range for healthy sheep.

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Frolov, A. V., and S. L. Pankov. "The effect of starvation on the biochemical composition of the rotiferBrachionus plicatilis." Journal of the Marine Biological Association of the United Kingdom 72, no. 2 (May 1992): 343–56. http://dx.doi.org/10.1017/s0025315400037747.

Повний текст джерела

Анотація:

Alterations of the biochemical composition and survival of the rotiferBrachionus plicatilishave been investigated. During starvation the proportion of total protein increased from 45·3 to 62·7% while that of total lipid, carbohydrate and glycogen decreased from 20·1 to 6·9%, from 21·2 to 14·1% and from 17·3 to 4·9% dry weight, respectively. The proportion of polar lipids and free sterols in total lipids increased, from 8·3 to 32·0% and from 29·2 to 58·3% whereas triacylglycerol decreased from 54·7 to 4·2% dry weight. The most abrupt alteration in these fractions took place in the interval from 24 to 48 h. The proportion of monoacylglycerols, diacylglycerols, free fatty acids and esters of waxes and sterols in-creased from 1·2 to 3·0% (72 h), from 0·2 to 1·8 (48 h), from 0·7 to 2·4 (72 h) and from 5·7 to 12·1% (48 h) and then decreased to the level of 1·1, 0·9, 1·2 and 1·3%, respectively.

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Kviklys, Darius, Mindaugas Liaudanskas, Jonas Viškelis, Loreta Buskienė, Juozas Lanauskas, Nobertas Uselis, and Valdimaras Janulis. "Composition and Concentration of Phenolic Compounds of ‘Auksis’ Apple Grown on Various Rootstocks." Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. 71, no. 3 (June 27, 2017): 144–49. http://dx.doi.org/10.1515/prolas-2017-0025.

Повний текст джерела

Анотація:

AbstractThe trial was carried out at the Institute of Horticulture, Lithuanian Research Centre for Agriculture and Forestry in 2013-2015. Cv. ‘Auksis’ was tested on 12 rootstocks: B.396, B.9, M.9, M.26, P 22, P 59, P 61, P 62, P 66, P 67, PB.4, and Pure 1. Accumulation of phenolic compounds depended on fruit yield and average fruit weight. On average, significantly lower concentration among rootstocks occurred when apple trees had abundant yield and fruits were smaller. On average chlorogenic acid constituted 50% and total procyanidins 28% of total phenols in ‘Auksis’ fruits. Flavonoid concentration most depended on rootstock and the highest variation was recorded. More than 50% difference occurred between the highest total flavonoid concentration in apples on PB.4 and the lowest on M.9 rootstocks. Low variability of total procyanidin concentration among rootstocks was observed. Differences between the highest and lowest concentration was 15%. Total concentration of phenolic compounds differed among rootstocks by 29-35% depending on the year. Differences in accumulation of phenolic compounds depended on rootstock genotype but not on yield or fruit weight. PB.4 and P 67 rootstocks had the highest, and M.9, P 62 and M.26 had the lowest concentration of total phenol in ‘Auksis’ fruits

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Parker, Haley W., Alison Tovar, Karen McCurdy, and Maya Vadiveloo. "Socio-economic and racial prenatal diet quality disparities in a national US sample." Public Health Nutrition 23, no. 5 (December 3, 2019): 894–903. http://dx.doi.org/10.1017/s1368980019003240.

Повний текст джерела

Анотація:

AbstractObjective:To examine differences in prenatal diet quality by socio-economic status (SES) and race/ethnicity.Design:A secondary, cross-sectional analysis. Race and SES were self-reported prenatally; SES was categorized into four groups: high-income, middle-income and low-income WIC (Special Supplemental Nutrition Program for Women, Infants, and Children) participant/non-participant. The Alternative Healthy Eating Index for Pregnancy (AHEI-P) measured diet quality, including four moderation and nine adequacy components (higher scores = healthier diet). Generalized linear models adjusted for covariates and post hoc testing with Tukey adjustment compared AHEI-P scores between groups, using a threshold of P < 0·05.Setting:Infant Feeding Practices Study II, conducted in a national US convenience cohort.Participants:Women in their third trimester (n 1322) with dietary history.Results:Participants were of 28·9 (se 5·6) years on average and predominantly non-Hispanic White (84 %); approximately one-third participated in WIC and 17 % were high-income. The mean AHEI-P score was 61·7 (se 10·8) of 130 points. High-income women had higher total (62·4 (se 1·0)) and moderation component AHEI-P scores than middle-income (60·1 (se 0·8), P = 0·02), low-income WIC participants (58·3 (se 0·8), P < 0·0001) and non-participants (58·9 (se 0·9), P = 0·001). Non-Hispanic Black participants had lower total (57·8 (se 1·4)) and adequacy scores than Other races (i.e. neither non-Hispanic Black nor White, 62·1 (se 0·9), P = 0·02).Conclusions:Disparities in prenatal diet quality were observed, with non-Hispanic Black women, low-/middle-income and WIC participants having lower diet quality. However, interventions are needed to improve prenatal diet quality broadly among US women.

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Escalante, Carmelita P., Ali Zalpour, Juhee Song, Marsha N. Richardson, Tony Lam, Josiah Halm, SWamique Yusuf, and Shuwei Gao. "Practice patterns and outcomes of rivaroxaban usage in patients with cancer." Journal of Clinical Oncology 34, no. 26_suppl (October 9, 2016): 194. http://dx.doi.org/10.1200/jco.2016.34.26_suppl.194.

Повний текст джерела

Анотація:

194 Background: Patients with cancer have an increased risk of venous thromboembolism (VTE) and frequently require anticoagulation. In addition, many patients with cancer also have comorbidities such as atrial fibrillation (AF) and are on stroke prevention. Rivaroxaban (RV) is an oral (factor Xa inhibitor) used in these scenarios; however, there is little experience utilizing this agent in patients with cancer. Our aim is to describe practice patterns and outcomes of RV usage in patients with cancer. Methods: We conducted a retrospective study of 62 patients with cancer receiving RV for at least 5 days for VTE or non-valvular AF from 1/1/2012 through 10/31/2015. Practice patterns included RV perioperative use and blood and platelet transfusions. Outcomes of interest were recurrent VTE and bleeding. Descriptive statistics were utilized to summarize demographic and clinical variables. Results: Of 62 patients with cancer, the mean age was 62 years (range 31-83), 50% were male, and 77% white. The most common cancer types were gastrointestinal 9 (15%), sarcoma 9 (15%), and breast and hematologic each with 8 (13%). Of those, 49 (79%) had VTE, 9 AF (15%), and 4 (7%) had both. 42 (68%) patients were switched to RV from a prior anticoagulant, the majority from low molecular weight heparin. 22 (36%) had RV withheld temporarily; 15 due to surgical procedure and 5 due to bleeding. 5 (33%) received bridging anticoagulation prior to surgery. RV was held a mean of 2 days prior to surgery and resumed 9 days post-op. 14 (21%) received blood and 2 (3%) received platelet transfusions while on RV. 2 (3%) patients had VTE recurrence while on RV. 18 (29%) discontinued RV due to bleeding, 5 (28%) due to hematuria and only 1 patient due to thrombocytopenia (6%). There were no major bleeds or deaths related to RV. Conclusions: RV was used in solid and hematologic cancers. The majority were transitioned from another anticoagulant. Although VTE recurrence was low, discontinuation of RV due to bleeding was higher. Further study of the use of RV in patients with cancer is needed for continued guidance of appropriate and safe usage.

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Wapshott, Robert. "The Bottom Line HR Function20061P. Kearns. The Bottom Line HR Function. Oxford: Chandos Publishing 2001. 215 pp., ISBN: 1‐902375‐62‐9 £35.00 (pbk)." Personnel Review 35, no. 3 (May 2006): 352–54. http://dx.doi.org/10.1108/00483480610656739.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Rowe, Penny M., Larry M. Miloshevich, David D. Turner, and Von P. Walden. "Dry Bias in Vaisala RS90 Radiosonde Humidity Profiles over Antarctica." Journal of Atmospheric and Oceanic Technology 25, no. 9 (September 1, 2008): 1529–41. http://dx.doi.org/10.1175/2008jtecha1009.1.

Повний текст джерела

Анотація:

Abstract Middle to upper tropospheric humidity plays a large role in determining terrestrial outgoing longwave radiation. Much work has gone into improving the accuracy of humidity measurements made by radiosondes. Some radiosonde humidity sensors experience a dry bias caused by solar heating. During the austral summers of 2002/03 and 2003/04 at Dome C, Antarctica, Vaisala RS90 radiosondes were launched in clear skies at solar zenith angles (SZAs) near 83° and 62°. As part of this field experiment, the Polar Atmospheric Emitted Radiance Interferometer (PAERI) measured downwelling spectral infrared radiance. The radiosonde humidity profiles are used in the simulation of the downwelling radiances. The radiosonde dry bias is then determined by scaling the humidity profile with a height-independent factor to obtain the best agreement between the measured and simulated radiances in microwindows between strong water vapor lines from 530 to 560 cm−1 and near line centers from 1100 to 1300 cm−1. The dry biases, as relative errors in relative humidity, are 8% ± 5% (microwindows; 1σ) and 9% ± 3% (line centers) for SZAs near 83°; they are 20% ± 6% and 24% ± 5% for SZAs near 62°. Assuming solar heating is minimal at SZAs near 83°, the authors remove errors that are unrelated to solar heating and find the solar-radiation dry bias of 9 RS90 radiosondes at SZAs near 62° to be 12% ± 6% (microwindows) and 15% ± 5% (line centers). Systematic errors in the correction are estimated to be 3% and 2% for microwindows and line centers, respectively. These corrections apply to atmospheric pressures between 650 and 200 mb.

Стилі APA, Harvard, Vancouver, ISO та ін.

33

RUPA, V., R. ISAAC, G. REBEKAH, and A. MANOHARAN. "Association of Streptococcus pneumoniae nasopharyngeal colonization and other risk factors with acute otitis media in an unvaccinated Indian birth cohort." Epidemiology and Infection 144, no. 10 (March 2, 2016): 2191–99. http://dx.doi.org/10.1017/s0950268816000248.

Повний текст джерела

Анотація:

SUMMARYIn order to study the epidemiology of acute otitis media (AOM) and Streptococcus pneumoniae nasopharyngeal colonization in the first 2 years of life, we followed up an unvaccinated birth cohort monthly and at visits when sick, with otoscopy to detect AOM and performed nasopharyngeal swabbing to detect S. pneumoniae. Serotyping of positive cultures was also performed. Of 210 babies who were enrolled at birth, 61 (29·05%) experienced 128 episodes of AOM [relative risk 2·63, 95% confidence interval (CI) 1·21–5·75] with maximum incidence in the second half of the first year of life. Episodes ranged from 1 to 7 (mean 2·1 episodes). Most (86·9%) babies with AOM had a positive culture swab giving an odds ratio (OR) of 1·93 (95% CI 1·03–3·62, P = 0·041) for this association. Other risk factors identified for AOM were winter season (OR 3·46, 95% CI 1·56–7·30, P = 0·001), upper respiratory infection (OR 2·43, 95% CI 1·43–4·51, P = 0·005); residents of small households were less likely to develop AOM (OR 0·32, 95% CI 0·17–0·57, P < 0·01). Common S. pneumoniae serotypes isolated during episodes were 19, 6, 15, 35, 7, 23, 9 and 10 which indicated a theoretical coverage for pneumococcal vaccines PCV10 and PCV13 constituent serotypes of 62·8%. We conclude that AOM in Indian infants is often associated with S. pneumoniae colonization of the nasopharynx as well as other risk factors.

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Marconi, Giovanni, Roberta di Nicola, Chiara Sartor, Mariachiara Abbenante, Jacopo Nanni, Gianluca Cristiano, Sarah Parisi, et al. "AML-CM Score Predicts Prognosis in Hemato-Geriatric Patients with New-Onset Acute Myeloid Leukemia (AML) Who Receive Hypomethylating Agents (HMA)." Blood 134, Supplement_1 (November 13, 2019): 2617. http://dx.doi.org/10.1182/blood-2019-130630.

Повний текст джерела

Анотація:

Background Although much efforts have been made to precisely define fitness of AML patients, in patients who are not candidate to chemotherapy, there is no prognostic model and the respective weight of AML biology and patient fitness are not well established. Here we test AML-CM score (Sorror, JAMA 2018), that is validated in fit population, in a set of old AML patients who received HMAs. Methods We retrospectively collected data of consecutive patients who received HMAs in our institution from 1st Jan 2008 with an age > 65 years at AML diagnosis. AML-CM score was applied to all the patients. Patients were divided in 4 groups (score 1-4: group 1, score 5-6: group 2; score 7-9: group 3, score > 9: group 4) and in 2 macro-groups (score 1-6: group A and score > 6 group B) for the analyses. Descriptive data are presented as median with interquartile ranges (IQR). Adverse events are graded according to CTCAE v4.03. Survival analysis was conducted with Kaplan-Meyer and are presented as 95% confidence intervals (C.I.) and differences in overall survival (OS) were tested with 2-side log rank test. Fisher exact test and Person's chi squared test were used whenever appropriate. Results At data cut-off, 1st Jan 2019, 60 consecutive patients received decitabine or azacytidine as 1st line therapy for AML. Median age of the population was 75.94 years (IQR 72.53-80.38). Most of the patients (37/62, 59.7%) had de novo AML, 19/62 (30.6%) had AML secondary to previous myeloid disorders and 6/62 (9.7%) had AML secondary to chemotherapy or radiotherapy. Most of the patients were smokers (19/33, 57.57%, 29 no data), and few were usual drinkers (4/16, 25.00%, 46 no data). In our set, out of 62 patients, 2 patients (3.2%) had inv(3), 1 (1.6%) a translocation involving 11q23, 1 (1.6%) del(5q), 4 (6.4%) mon(7) or del (7q), 1 (1.6%) del(17p), 15 (24.2%) complex karyotype, 27 (43.5%) normal karyotype, 4 (6.5%) other alterations and 5 were not evaluable; 3/17 (17.65%, 45 no data) harbored IDH2 mutation, 1/16 (6.25%) IDH2 mutation, 2/33 FLT3 mutation (6.06%, 29 no data), 1/24 (4.17%, 38 no data), 2/15 (13.33%, 47 no data) TP53 mutation. According to ELN 2017, 3/62 patients (4.83%) had low risk, 34/62 (54.84%) intermediate risk and 23/62 (37.10%) high risk AML. According to AML-CM score, 13/62 patients (20.97%) were in group A, 20/62 (32.36%) in group B, 21/62 (33.87%) in group C, 6/62 (9.68%) in group D, 2/62 (3.23%) were not allocated for incomplete AML-CM score. There was no difference in term of age, ELN risk, secondary AML prevalence, HMA administered, or response to HMA according to ELN criteria between group 1, 2, 3, 4 or between macro-group A and B. Cardiovascular comorbidity, diabetes mellitus, obesity, previous tumor, hypoalbuminemia, elevated LDH were prevalent in higher risk AML-CM groups (3-4) and in macro-group B. Median OS was 658 days (95% C.I. 316-1000) in group 1, 556 days (95% C.I. 463-649 in group 2, 243 days (95% C.I. 153-353) in group 3, 107 days (95% C.I. 47-167) in group 4 (p=.021, figure 1A). Furthermore, we observed a median OS of 589 days (95% C.I. 328-850) in macro-group A and 219 days (95% C.I. 96-342) in macro-group B (p=.003, figure 1B). Reduced survival was correlated with a non-statistical trend toward augmented incidence of infections and adverse events in higher risk AML-CM groups (3-4). Conclusions AML-CM is a useful indicator of prognosis in old patients that receive HMAs. Prognosis in our set is influenced by comorbidity (measured with AML-CM, a quantitative score) more than by disease biology. We identified a group of patients (macro-group A) that has median OS after HMAs outlying OS reported in literature. This brilliant result can be due to lower comorbidity. AML-CM could help in defining candidate patients for therapy intensification and care utilization or for team comorbidity management. GM and RDN equally contributed Figure 1 Disclosures Martinelli: Roche: Consultancy; Novartis: Consultancy; ARIAD: Consultancy; BMS: Consultancy; Pfizer: Consultancy. Baccarani:Novartis: Consultancy, Speakers Bureau; Incyte: Consultancy, Speakers Bureau; Takeda: Consultancy. Papayannidis:Pfizer: Honoraria; Teva: Honoraria; Shire: Honoraria; Novartis: Honoraria; Amgen: Honoraria; Incyte: Honoraria. Cavo:janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel accommodations, Speakers Bureau; bms: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel accommodations, Speakers Bureau; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; novartis: Honoraria; takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau.

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Elezovic, Ivo, Darinka Boskovic, Milica Colovic, Dragica Tomin, Nada Suvajdzic-Vukovic, Mirjana Gotic, Radoje Colovic, and M. Popovic. "Long term follow up of splenectomised patients with idiopathic thrombocytopenic purpura." Acta chirurgica Iugoslavica 49, no. 3 (2002): 29–34. http://dx.doi.org/10.2298/aci0203029e.

Повний текст джерела

Анотація:

Splenectomy is definitive treatment for idiopathic thrombocytopenic purpura (ITP) because it removes both the sites of autoantibody producing cells and also the major site of platelet destruction. The purpose of this study was to evaluate long term results of splenectomised patients with ITP and to determine predictor factors for good response. A 167 patients with chronic ITP (136 females, 31 males), median aged 35 years (17-74) was splenectomised after 2 to 160 months (Median 12) from diagnosis of ITP. Indications for splenectomy were: 6 weeks of steroid therapy with platelet count below 10x10^9/l or 3 months with platelet count under 30xl0^9/l, or treatment with prednisone above 30 mg more of 6 months to increase platelet count over 30x10^9/l, or repeated relapses. Postoperative complications developed in 16 patients (9.5%), 3 of them died (1.8%) due to thromboembolism and 17 patients discontinued later controls. During follow up to 172 months (Median 62) 111/147 splenectomised patients were in remission (75.5%), 99 in complete (above 100x10^9/l), 12 in partial (50-100x109/l) and 36 patients (24.5%) were relapsed (below 50x10^9/l). Remission was achieved in 79/88 patients (89.8%) with good response to prednisone before splenectomy toward 32/62 patients (51.6%) with poor response to prednisone (p<0.01). Remission was obtained in 9/11 patients (81.8%) who responded well to intravenous immune globulin (0.4 g/kg x 5d) and only in 1/8 who did not (p<0.05). Higher response rate was achieved in patients under 40 years of age (81.6%) than in older ones (63.4%) (p<0.05). No difference was shown between sex and time intervals (3, 6, 12, 24, 36 or over 36 months) from diagnosis to splenectomy. Splenectomy is an effective treatment of refractory ITP with response rate of 75.5% after median follow up of 62 months. In our patients better results on splenectomy were associated with age less than 40 years, good responses to steroid, and intravenous immune globulin.

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Rock, Gail, David Anderson, Barrett Benny, William Clark, Pierre Leblond, David Sutton, Marion Sternbach, and George Wells. "Treatment of Thrombotic Thrombocytopenic Purpura Using Solvent Detergent Treated Plasma." Blood 106, no. 11 (November 16, 2005): 3989. http://dx.doi.org/10.1182/blood.v106.11.3989.3989.

Повний текст джерела

Анотація:

Abstract Background: Patients with Thrombotic Thrombocytopenic Purpura require immediate therapy with large volumes of plasma. They have been reported to respond well to plasma exchange (PE) with FFP (78%)1 and CSP (95%)2. We initiated a randomized prospective trial with CSP and solvent detergent treated plasma (SDP) intended to show non inferiority. Methods: Patients were randomized to receive either of the exchange fluids at 1.5 PV x 3 days then 1 PV x 4–6 days. Laboratory values were followed with ADAMTS-13 levels measured according to Furlan3. The primary end point was survival at 6 months. Results: A total of 62 of the required 280 patients entered the study then the supply of SDP was discontinued. 3/35 patients receiving CSP and 1/27 on SDP died before 1 month. These values are not significant but the study is underpowered so statistical analysis is not possible. FVIII and vWF levels were elevated in all patients at entry. 34/50 patients tested also had antibodies to CD36. 9 patients had no ADAMTS-3 at entry, 19 had between 5–50%, 9 patients had 50–100% and 15/62 patients tested had normal levels. Inhibitors were present at between 5–50% levels in 22/50 patients tested whereas 9 patients had complete inhibition of ADAMTS-13 and 18 had normal enzyme activity. Conclusions: Patients with TTP appear to respond well to SDP thereby offering a relatively safer therapeutic option for PE. An insufficient number of patients were entered to achieve statistical significance. Both the ADAMTS-13 and the inhibitor levels show great variation and are not prognostic.

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Aleshkin, Konstantin, and Anton Izosimov. "Euler equations on the general linear group, cubic curves, and inscribed hexagons." L’Enseignement Mathématique 62, no. 1 (2016): 143–70. http://dx.doi.org/10.4171/lem/62-1/2-9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

38

DUNCAN, J. S., A. J. H. LEATHERBARROW, N. P. FRENCH, and D. H. GROVE-WHITE. "Temporal and farm-management-associated variation in faecal-pat prevalence ofCampylobacter fetusin sheep and cattle." Epidemiology and Infection 142, no. 6 (September 25, 2013): 1196–204. http://dx.doi.org/10.1017/s0950268813002379.

Повний текст джерела

Анотація:

SUMMARYThe faecal-pat prevalence (as estimated by culture) ofCampylobacter fetusfrom cattle and sheep on 19 farms in rural Lancashire was investigated using standardCampylobacterculture techniques and PCR during a 2-year longitudinal study.C. fetuswas isolated from 9·48% [95% confidence interval (CI) 8·48–10·48] of cattle faecal pats and 7·29% (95% CI 6·21–9·62) of sheep faecal pats. There was evidence of significant differences in shedding prevalence between geographical regions; cows in geographical zone 3 had an increased risk of sheddingC. fetuscompared to cows in geographical zones 1 and 2 (OR 6·64, 95% CI 1·67–26·5,P = 0·007), as did cows at pasture (OR 1·66, 95% CI 1·01–2·73,P = 0·046) compared to when housed. Multiple logistic regression modelling demonstrated underlying seasonal periodicity in both species.

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Roy, B., G. Mondal, D. Nanda, S. Das, and MK Das. "Kearns-Sayre Syndrome: A Rare Mitochondrial Deletion Disorder." Journal of Nepal Paediatric Society 33, no. 1 (June 15, 2013): 61–62. http://dx.doi.org/10.3126/jnps.v33i1.6696.

Повний текст джерела

Анотація:

A 9 yr girl presented with bilateral ptosis and deafness of gradual onset for the last four years. Associated ophthalmoplegia and pigmentary retinopathy, heart block, raised CSF protein and serum lactate was suggestive of the diagnosis of Kearns-Sayre syndrome (KSS), a rare entity in the spectrum of the mitochondrial deletion syndrome. Search for endocrinopathy revealed no abnormality. DOI: http://dx.doi.org/10.3126/jnps.v33i1.6696 J Nepal Paediatr Soc. 2013;33(1):61-62

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Pemmaraju, Naveen, Deborah A. Thomas, Hagop Kantarjian, Susan Mary O'Brien, Naval Guastad Daver, Aziz Nazha, Sherry Pierce, Guillermo Garcia-Manero, Jorge E. Cortes, and Stefan Faderl. "Analysis of outcomes of patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN)." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 6578. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.6578.

Повний текст джерела

Анотація:

6578 Background: BPDCN, formerly known as CD4 + CD56 + hematodermic tumor or blastic NK cell lymphoma, is a rare and aggressive hematologic malignancy. Little is known about outcomes of pts with BPDCN. Methods: We conducted a retrospective review of pts meeting following criteria: pathological diagnosis of BPDCN confirmed by an experienced hematopathologist and age ≥ 18. Results: 13 pts, diagnosed October 1998-July 2011, were identified. Median (med) age: 62 years (range 20-86 years), 12 (92%) were male. Bone marrow (BM) involved in 9 (69%), skin 8 (62%), lymph nodes 5 (38%), brain 1 and uterine/ovarian 1 pt. Immunophenotype by flow cytometry: CD4+ (11/11 pts), CD56+ (10/11 pts), TCL-1+ (4/4 pts). Karyotype (8 pts): del(12) (1pt), complex (2), and diploid (5). Med CBC: WBC 5.8 x 109/L (1.7-76.5), Hb 12.3 g/dL (8.3-17.0), platelet 107 x 109/L (44-255). Med BM blasts: 22% (0-77). 10 pts received first-line therapy with Hyper-CVAD alternating with high-dose methotrexate(MTX) and cytarabine (HCVAD) (in 1 pt following one cycle of CHOP), CHOP (2), oral MTX (1). Med follow-up time: 9 months (mo) (2-14 mo). Med number chemotherapy regimens: 1 (1-5). Complete remission (CR) in 10 pts. Med CR1: 19 mo (4-39 mo). Med overall survival (OS) 29 mo (1-44 mo). 9 pts have died, unknown cause (3), multi-organ failure (6). 10 pts received HCVAD as part of first line therapy: med OS: 29 mo (1-44 mo), med CR1: 21 mo (4-39 mo), 9/10 (90%) pts achieved CR1; 1 pt did not achieve CR1 (died, pneumonia, day 15). 9 pts (69%) had BM involvement (7 with other organs involved besides BM). 4 (31%) pts had no BM involvement; all 4 of these pts had skin involvement only. Med OS, med CR1 of pts with BM involvement: 23 mo (1-44mo), 22 mo (4-39mo), respectively. Med OS, med CR1 of skin only pts: 29 mo (2-31 mo), 7 mo (6-19 mo), respectively, p=not significant. 4 pts received stem cell transplant (SCT) (2 allogeneic ,2 autologous). Med OS for pts receiving SCT (n=4) was 31 mo(8-31 mo) versus med OS for non-SCT group (n=9) of 29 mo (1-44), p=not significant. Conclusions: Despite intensive multi-agent chemotherapy and SCT, response rates are low and survival is short. Better understanding of the biologic basis of this disease and novel treatment approaches for treatment of BPCDN are crucial.

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Шпрах, Зоя С., Л. М. Борисова, М. П. Киселева та З. С. Смирнова. "Доклиническое изучение противоопухолевой активности цифетрилина на экспериментальных опухолях животных". Экспериментальная и клиническая фармакология 82, № 8 (22 вересня 2019): 27–31. http://dx.doi.org/10.30906/0869-2092-2019-82-8-27-31.

Повний текст джерела

Анотація:

Представлены результаты изучения противоопухолевой активности отечественного аналога соматостатина цифетрилина на экспериментальных опухолях животных. Выявлен максимальный противоопухолевый эффект цифетрилина в дозе 10 мг/кг на перевиваемой модели рака шейки матки РШМ5 непосредственно после окончания применения препарата (торможение роста опухоли, ТРО = 86 %). Показано, что цифетрилин в дозе 120 мг/кг способствовал увеличению продолжительность жизни (УПЖ) животных с аденокарциномой Са755 на 59 % (ТРО = 86 %). Препарат подавлял рост аденокарциномы толстой кишки АКАТОЛ в течение 9 дней: ТРО = 79 % и 62 % в 1-й и 9-й день наблюдения, соответственно, а меланомы В16 — в течение 17 дней, ТРО = 77 – 62 %. Установлено, что режим ежедневного перорального введения препарата в течение 5 дней является наиболее эффективным: на РШМ5 эффект цифетрилина оставался статистически достоверным (ТРО = 54 %) до 22-го дня наблюдения, а на Са755, АКАТОЛе и меланоме В16 — на протяжении 14 дней (ТРО 82, 58 и 59 %, соответственно). Показаны высокая противоопухолевая эффективность цифетрилина в отношении развившейся опухоли РШМ5 (ТРО = 79 – 76 %), а также антиметастатическая эффективность препарата (61 % торможения роста метастазов) в комбинации с хирургическим удалением опухоли.

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Garcia-Manero, Guillermo, Sarit Assouline, Jorge Cortes, Zeev Estrov, Hagop Kantarjian, Hui Yang, Willie M. Newsome, et al. "Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia." Blood 112, no. 4 (August 15, 2008): 981–89. http://dx.doi.org/10.1182/blood-2007-10-115873.

Повний текст джерела

Анотація:

Abstract MGCD0103 is an isotype-selective inhibitor of histone deacetylases (HDACs) targeted to isoforms 1, 2, 3, and 11. In a phase 1 study in patients with leukemia or myelodysplastic syndromes (MDS), MGCD0103 was administered orally 3 times weekly without interruption. Twenty-nine patients with a median age of 62 years (range, 32-84 years) were enrolled at planned dose levels (20, 40, and 80 mg/m2). The majority of patients (76%) had acute myelogenous leukemia (AML). In all, 24 (83%) of 29 patients had received 1 or more prior chemotherapies (range, 0-5), and 18 (62%) of 29 patients had abnormal cytogenetics. The maximum tolerated dose was determined to be 60 mg/m2, with dose-limiting toxicities (DLTs) of fatigue, nausea, vomiting, and diarrhea observed at higher doses. Three patients achieved a complete bone marrow response (blasts ≤ 5%). Pharmacokinetic analyses indicated absorption of MGCD0103 within 1 hour and an elimination half-life in plasma of 9 (± 2) hours. Exposure to MGCD0103 was proportional to dose up to 60 mg/m2. Analysis of peripheral white cells demonstrated induction of histone acetylation and dose-dependent inhibition of HDAC enzyme activity. In summary, MGCD0103 was safe and had antileukemia activity that was mechanism based in patients with advanced leukemia.

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Scott, Emma S., Rachel T. McGrath, Andrzej S. Januszewski, Daniel Calandro, Anandwardhan A. Hardikar, David N. O'Neal, Gregory Fulcher, and Alicia J. Jenkins. "HbA1c variability in adults with type 1 diabetes on continuous subcutaneous insulin infusion (CSII) therapy compared to multiple daily injection (MDI) treatment." BMJ Open 9, no. 12 (December 2019): e033059. http://dx.doi.org/10.1136/bmjopen-2019-033059.

Повний текст джерела

Анотація:

ObjectiveTo determine if continuous subcutaneous insulin infusion (CSII) therapy is associated with lower glycated haemoglobin (HbA1c) variability (long-term glycaemic variability; GV) relative to multiple daily injection (MDI) treatment in adults with type 1 diabetes mellitus (T1DM).DesignRetrospective audit.Setting and participantsClinic records from 506 adults with T1DM from two tertiary Australian hospitals.Outcome measuresLong-term GV was assessed by HbA1c SD and coefficient of variation (CV) in adults on established MDI or CSII therapy, and in a subset changing from MDI to CSII.ResultsAdults (n=506, (164 CSII), 50% women, mean±SD age 38.0±15.3 years, 17.0±13.7 years diabetes, mean HbA1c 7.8%±1.2% (62±13 mmol/mol) on CSII, 8.0%±1.5% (64±16 mmol/mol) on MDI) were followed for 4.1±3.6 years. CSII use was associated with lower GV (HbA1c SD: CSII vs MDI 0.5%±0.41% (6±6 mmol/mol) vs 0.7%±0.7% (9±8 mmol/mol)) and CV: CSII vs MDI 6.7%±4.6% (10±10 mmol/mol) vs 9.3%±7.3% (14±13 mmol/mol), both p<0.001. Fifty-six adults (73% female, age 36±13 years, 16±13 years diabetes, HbA1c 7.8%±0.8% (62±9 mmol/mol)) transitioned from MDI to CSII. Mean HbA1c fell by 0.4%. GV from 1 year post-CSII commencement decreased significantly, HbA1c SD pre-CSII versus post-CSII 0.7%±0.5% (8±5 mmol/mol) vs 0.4%±0.4% (5±4 mmol/mol); p<0.001, and HbA1c CV 9.2%±5.5% (13±8 mmol/mol) vs 6.1%±3.9% (9±5 mmol/mol); p<0.001.ConclusionsIn clinical practice with T1DM adults relative to MDI, CSII therapy is associated with lower HbA1c GV.

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Moura, Bianca Gautron, Camille Léa Gérard, Nathalie Testart, Marian Caikovsky, Alexandre M. Wicky, Veronica Aedo-Lopez, Grégoire Berthod, et al. "Adverse events and estimated costs with the combination of ipilimumab and nivolumab in metastatic melanoma patients." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): e21529-e21529. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e21529.

Повний текст джерела

Анотація:

e21529 Background: The combination of ipilimumab and nivolumab in metastatic melanoma patients increases response rates (RR) and survival outcomes. As checkpoint inhibitors bear a significant financial impact on the healthcare system, we performed a study that addresses the global costs of the treatment, focusing on immune-related adverse event (irAE) management costs. Methods: We conducted a retrospective analysis of 62 metastatic melanoma patients treated with ipilimumab and nivolumab at the Oncology Department of Lausanne University Hospital (CHUV) between June 1, 2016 and August 31, 2019. The frequency of irAEs, the duration, management, and outcomes were evaluated. All melanoma-specific costs were analyzed by mining the electronic healthcare record and billing data of the hospital. Results: The median follow-up was 32 months (range 20-1066 days). In our cohort, 54/62 (87%) patients presented at least one irAE, and 22/62 (35%) presented a grade 3 irAE. One patient died from an irAE (pneumonitis). The most common irAEs were diarrhea 23/62 (37%) any grade, 8/62 (13%) grade 3-4; hepatitis 22/62 (36%) any grade, 9/62 (15%) grade 3-4; and skin rash 21/62 (34%) any grade, 6/32 (10%) grade 3-4. The overall response rate was 29/62 (47%), with 15/62 (24%) of complete response (CR) and 14/62 (23%) of partial response (PR). The majority of patients who had a CR 13/15 (87%) and 20/28 (71%) of overall responders presented a grade 3-4 toxicity, and there were no responses in patients without toxicity. However, toxicity does not imply response, as only 29/54 (54%) of patients with toxicity (any grade) and 20/31 (65%) (grade 3-4) responded. The toxicity costs represent only 3% on average of the total expenses per patient. The most significant contributions were medication costs (44%) and disease costs (39%, mainly disease-related hospitalization costs). Patients with a CR had the lowest global cost per week (2,860 USD, converted from CHF) despite the associated toxicities and patients who had progressive disease, the highest one (9,999 USD). Except for the one patient who had a grade 5 toxicity (7,472 USD/week), we observe that less severe toxicity grades (11,603 USD/week for grade 1), or even the absence of toxicity (12,266 USD/week), are associated to higher median costs per week (against 4,039 USD/ week for grade 4 and 3,524 USD/week for grade 3). Conclusions: The cost of toxicities was unexpectedly small (only 3%) compared to the total costs, especially medication costs (44%). Also, patients with a higher degree of toxicity had lower costs and better outcomes.

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Afzal, Fariha, Muhammad Imran Khan, and Zenab. "Role of Coronary Calcium Score as a Screening Tool for Excluding Significant Coronary Artery Disease in High Risk Asymptomatic Patients." Journal of Gandhara Medical and Dental Science 9, no. 1 (January 7, 2022): 64–68. http://dx.doi.org/10.37762/jgmds.9-1.158.

Повний текст джерела

Анотація:

OBJECTIVES: To determine correlation of zero coronary artery calcium score (CACS) with non-significant coronary artery stenosis by using computed tomography coronary angiography (CTCA). METHODOLOGY: 62 patients with suspected coronary artery disease (CAD) underwent CACS test and CTCA from April 2018 to November 2020. Patients were examined with 160 slice multidetector CT and grouped according to their age, gender, CACS, and maximum coronary luminal stenosis. CACS was assessed using Agatston scoring and degree of stenosis was assessed by automatic software and severity was scored according to CAD-RADS. The correlation between these two main variables was calculated using Spearman rank correlation. RESULTS: The 62 patients were divided into four groups according to CACS, using the Agatston Unit (AU). Group 1; 0 AU (41 patients, 66.13%), Group 2; 1-100 AU (13 patients, 20.97%) Group 3; 101-400 AU (4 patients, 6.45%), Group 4; 401-1000 AU (4 patients, 6.45%). In 41 patients with zero calcium score (32 males and 9 females), 38 patients (92.68%) were found to have no coronary artery stenosis, 2 patients (4.87%) had mild coronary artery stenosis and 1 patient (2.43%) had moderate coronary artery stenosis. Total 35 patients presented for screening purpose out of which 25 (71%) had zero calcium score and no significant coronary artery disease. CONCLUSION: In high risk patients, zero calcium score excludes significant coronary artery stenosis (50%), hence coronary calcium score is a good screening tool before subjecting patients to coronary angiography.

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Alam, Zahangir, Sunam Kumar Barua, and Kishore Mohajan. "Soft Tissue Rheumatological Conditions of Patients Visited in An OPD of a Tertiary Care Hospital." Chattagram Maa-O-Shishu Hospital Medical College Journal 21, no. 1 (May 19, 2022): 11–13. http://dx.doi.org/10.3329/cmoshmcj.v21i1.59750.

Повний текст джерела

Анотація:

Background: Soft tissue rheumatological conditions are common but largely unexplored. So the objective of the present study was to see the different soft tissue rheumatological conditions presenting in OPD of a tertiary care center. Materials and methods: Present observational study conducted on 62 patients visiting the Physical Medicine OPD, Chattogram Maa-O-Shishu Hospital for different soft tissue rheumatological conditions were included in the study. Study period was six months from January 2020 to June 2020. After informed written consent patients were introduced a questionnaire and data was collected. Non-probability sampling method was adopted for the study. Data was analyzed by SPSS-20 Results: Among 62 patients gender distributions of patients revealed male was 24(38.7%) and female was 38(61.3%) and age group showing 15(24.2%) patients were at <30 years, 15(24.2%) patients were at 31-40 years, 13(21.0%) patients were at 41-50 years, 9(14.5%) patients were at 51- 60 years, 9(14.5%) patients were at 61-70 years and 1(1.6%) patient was at >71 years age group. Regarding occupations of the study patients 35(56.5%) patients were service holder, 24(38.7%) were doing business, 1(1.6%) patients was farmer, 1(1.6%) was fisherman and 1(1.6%) patients was housewife. Among all 9(14.5%) patients had DM and same number of patients also has HTN. Diagnosis of the soft tissue rheumatological conditions revealed 13(21%) patients had panter fassitis, 1(1.6%) patient had achillis tendinitis, 4(6.5%) patients had patellar tendinitis, 6(9.7%) patients had trochantaric bursitis, 1(1.6%) had tennis elbow, 3(4.8%) had golfer elbow, 191.6%) had De Quarven’s tenosinovitis, 5(8.1%) patients had trigger finger, 18(29.0%) patients had bicep tendinitis, 4(6.5%) patients had suspinatus tendinitis, 5(8.1%) patients had retrocalcaneal bursitis and 1(1.6%) patient had prepatellar bursitis. Conclusion: Soft tissue rheumatological diseases are common in OPD visits and needs proper attention for better patients care. Chatt Maa Shi Hosp Med Coll J; Vol.21 (1); January 2022; Page 11-13

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Türkmen, Yağmur, and Filiz Ertunç. "Determination of Grapevine Leafroll Diseases Infection in Turkey." Turkish Journal of Agriculture - Food Science and Technology 7, no. 11 (November 23, 2019): 1947. http://dx.doi.org/10.24925/turjaf.v7i11.1947-1953.2913.

Повний текст джерела

Анотація:

During the growing seasons between 2009 and 2010, totally 213 shoot and leaf samples were collected from the vineyards in Manisa, Denizli, Nevşehir, Elazığ, İzmir, Ankara, Çanakkale, Tekirdağ, Edirne and Kırklareli, which are commercially important viticulture production areas of Turkey. All grapevine samples were serologically investigated for the presence of Grapevine leafroll-associated viruses (GLRaVs) using GLRaV-1, GLRaV-2, GLRaV-3, GLRaV 4-9, GLRaV-6 and GLRaV-7 DAS-ELISA kits. In 143 of total, (67.14%) single or multiple infections were detected. GLRaV4-9, -7, -3, -1, -2 and -6 were detected as 53.52%, 36.15%, 34.74%, 32. 86%, 32.39% and 3.28%, respectively in the surveyed area. Eastern Anatolia Region had the highest infection rate (100%), followed by Marmara, Aegean, and Central Anatolia Region (69.74%, 75%, 62% and 26.47%, respectively). While the highest infection rates were obtained in Marmara Region for GLRaV-1, -2 and -3 as 43.42%, 44.74% and 50% respectively, GLRaV4-9 found as 100% in Eastern Anatolia Region. The highest infection rate was detected in Marmara Region for GLRaV-6 as 3.95%. The most common multiple infection was determined as GLRaV-1, -2, -3, 4-9 and -7 with the rate of 36.17%.

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Parlevliet, Edwin T., Judith E. de Leeuw van Weenen, Johannes A. Romijn, and Hanno Pijl. "GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet." American Journal of Physiology-Endocrinology and Metabolism 299, no. 2 (August 2010): E318—E324. http://dx.doi.org/10.1152/ajpendo.00191.2010.

Повний текст джерела

Анотація:

Glucagon-like peptide-1 (GLP-1) improves insulin sensitivity in humans and rodents. It is currently unknown to what extent the (metabolic) effects of GLP-1 treatment are mediated by central GLP-1 receptors. We studied the impact of central GLP-1 receptor (GLP-1R) antagonism on the metabolic effects of peripheral GLP-1 administration in mice. High-fat-fed insulin-resistant C57Bl/6 mice were treated with continuous subcutaneous infusion of GLP-1 or saline (PBS) for 2 wk, whereas the GLP-1R antagonist exendin-9 (EX-9) and cerebrospinal fluid (CSF) were simultaneously infused in the left lateral cerebral ventricle (icv). Glucose and glycerol turnover were determined during a hyperinsulinemic euglycemic clamp. VLDL-triglyceride (VLDL-TG) production was determined in hyperinsulinemic conditions. Our data show that the rate of glucose infusion necessary to maintain euglycemia was significantly increased by GLP-1. Simultaneous icv infusion of EX-9 diminished this effect by 62%. The capacities of insulin to stimulate glucose disposal and inhibit glucose production were reinforced by GLP-1. Simultaneous icv infusion of EX-9 significantly diminished the latter effect. Central GLP-1R antagonism alone did not affect glucose metabolism. Also, GLP-1 treatment reinforced the inhibitory action of insulin on VLDL-TG production. In conclusion, peripheral administration of GLP-1 reinforces the ability of insulin to suppress endogenous glucose and VLDL-TG production (but not lipolysis) and boosts its capacity to stimulate glucose disposal in high-fat-fed C57Bl/6 mice. Activation of central GLP-1Rs contributes substantially to the inhibition of endogenous glucose production by GLP-1 treatment in this animal model.

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Calamelli, Elisabetta, Carlo Caffarelli, and Giampaolo Ricci. "Peanut Sensitization Profiles in Italian Children and Adolescents with Specific IgE to Peanuts." BioMed Research International 2013 (2013): 1–5. http://dx.doi.org/10.1155/2013/170452.

Повний текст джерела

Анотація:

Peanuts are one of the most relevant foods implicated in IgE-mediated adverse reactions in pediatric population. This study aimed to evaluate the pattern of sensitization towards five peanut allergenic components (rAra h 1, 2, 3, 8 and 9) in a population of Italian children and adolescents with specific IgE (sIgE) to peanut. rAra h 9 was the main allergen implicated in peanut sensitization (58%), followed by rAra h 8 (35%), rAra h 2 (27%), rAra h 3 (23%) and rAra h 1 (12.5%). rAra h 1, 2, and 3 were the main allergenic components in young children: 8/13 (62%) between 2 and 5 years, 8/23 (35%) between 6 and 11 years, and 3/12 (25%) between 1 and 16 years. No differences were found among the levels of sIgE towards rAra h 1, 2, 3, and 9 in the three groups; in contrast, the levels of sIgE against rAra h 8 showed an increasing trend according to age. In conclusion rAra h 1, 2, and 3 were the prevalent sensitizing allergens during the first years of life in Italian patients with sIgE to peanuts (“genuine” allergy); in contrast rAra h 9 and 8 were mainly involved in school-age children and adolescents with pollen allergy (“secondary” sensitization).

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Ovens, Katie Jane, John Joseph Reynolds-Wright, Elizabeth Louise Anne Cross, Lucinda Rickwood, Mohammed Osman Hassan-Ibrahim, and Suneeta Soni. "High rates of treatment failure for Mycoplasma genitalium among men and women attending a sexual health clinic." BMJ Sexual & Reproductive Health 46, no. 2 (November 13, 2019): 132–38. http://dx.doi.org/10.1136/bmjsrh-2019-200384.

Повний текст джерела

Анотація:

BackgroundMycoplasma genitalium (Mgen) causes non-gonococcal urethritis (NGU) and is believed to cause pelvic inflammatory disease (PID). High rates of macrolide resistance are well documented globally for Mgen. In Brighton, patients with NGU and PID are tested for Mgen and test of cure (TOC) offered post-treatment.MethodsDemographic, clinical and treatment history data were collected over a 12-month period for all Mgen-positive patients in a Brighton-based genitourinary clinic.ResultsThere were 114 patients with Mgen. 18% (61/339) of men with NGU and 9% (15/160) of women with PID had Mgen. 62/114 (54%) returned for first test TOC 4 weeks after treatment. 27/62 (44%) had a positive TOC; 25/27 (92.6%) had received azithromycin first line (500 mg stat then 250 mg OD for 4 days), 1/27 (3.7%) had received moxifloxacin first line (400 mg OD for 14 days) and 1/27 (3.7%) had received doxycycline first line (100 mg BD for 7 days). 20/27 (74%) returned for a second TOC 4 weeks later. 5/20 (25%) patients were positive on second TOC; 3/5 (60%) had received azithromycin second line and 2/5 (40%) had received moxifloxacin second line. Patients were more likely to have a positive TOC if they were at risk of reinfection (9/27 positive TOC vs 3/35 negative TOC; p=0.02). Patients given moxifloxacin were more likely to have a negative TOC (1/27 positive TOC vs 9/35 negative TOC; p=0.03) than those who received other antibiotic regimens.ConclusionsTreatment failure rates for Mgen following azithromycin use are substantial, raising concerns regarding resistance. However, reinfection risk may contribute, suggesting a requirement for improved public awareness and clinician knowledge.

Стилі APA, Harvard, Vancouver, ISO та ін.

Статті в журналах з теми "62-1/-9"

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями